Dr. Yuan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
10 Congress St Ste 200
Pasadena, CA 91105Phone+1 424-314-0190Fax+1 424-314-0193
Education & Training
NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2006 - 2009- NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2006 - 2007
New York Downtown HospitalResidency, Internal Medicine, 2003 - 2006
Xuzhou Medical CollegeClass of 1994
Certifications & Licensure
CA State Medical License 2009 - 2027
LA State Medical License 2021 - 2022
NY State Medical License 2009 - 2012- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
- Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer Start of enrollment: 2014 Oct 01
Publications & Presentations
PubMed
- 3 citationsNeoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status.Melinda L Telli, Jennifer K Litton, J Thaddeus Beck, Jason M Jones, Jay Andersen
Breast Cancer. 2024-09-01 - 1 citationsUGT1A1*28 polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan.Megan H Wong, Veronica C Jones, Wai Yu, Linda D Bosserman, Sayeh M Lavasani
Cancer Medicine. 2024-08-01 - 8 citationsAuthor Correction: Comprehensive molecular characterization of mitochondrial genomes in human cancers.Yuan Yuan, Young Seok Ju, Youngwook Kim, Jun Li, Yumeng Wang
Nature Genetics. 2023-05-01
Journal Articles
- ERα-Mediated Cell Cycle Progression Is an Important Requisite for CDK4/6 Inhibitor Response in HR+ Breast CancerJoanne Mortimer, Laura Kruper, Raju Pillai, George Somlo, Yuan Yuan, Oncotarget
Press Mentions
TNBC: Distinct Tumor Immune Microenvironments at Metastatic SitesJune 26th, 2024
Professional Memberships
- Member
Other Languages
- Chinese (Mandarin)
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
